Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host

Summary

Open label non-randomized multicenter phase 2 trial with direct individual benefice

Timeline

Start

2012-12-24

Primary completion

2017-07-26

Completion

2017-07-26

Publications

• Results Srour M, Alsuliman T, Labreuche J, Bulabois CE, Chevallier P, Daguindau E, Forcade E, Francois S, Guillerm G, Coiteux V, Turlure P, Beguin Y, Yakoub-Agha I, Magro L. Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bone Marrow Transplant. 2023 Apr;58(4):401-406. doi: 10.1038/s41409-022-01898-x. Epub 2023 Jan 9.

Drugs

Indications